Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Torsdag 31 Oktober | 13:17:19 Europe / Stockholm

Svenska | English

BioStock

Biosergen AB: BioStock: Biosergen advances BSG005 antifungal drug candidate trial

2024-10-18 08:20:47

Biosergen is advancing its drug candidate BSG005, designed as a rescue treatment for patients with invasive fungal infections. The company has enrolled the first cohort in their phase Ib Proof-of-Concept trial, with 5 out of a total of 15 patients included so far. Biosergen's CEO, Tine Olesen, came to BioStock's studio to discuss this milestone, the company's financing and the next steps ahead.

See the interview with CEO Tine Olesenat biostock.se:

https://www.biostock.se/en/2024/10/biosergen-advances-bsg005-antifungal-drug-candidate-trial/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

BioStock

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden